PDCD1 and bladder transitional cell carcinoma: Similarly, in other tumor types like malignant melanoma [26], non-small cell lung cancer [27], and urothelial bladder cancer [28], it has been shown that PD-L1-positive tumors have a significantly higher response rate to anti-PD-1/PD-L1 therapy.